Inhibition of vascular adhesion protein-1 enhances the anti-tumor effects of immune checkpoint inhibitors.
Amine Oxidase (Copper-Containing)
/ antagonists & inhibitors
Animals
CD8-Positive T-Lymphocytes
/ drug effects
Cell Adhesion Molecules
/ antagonists & inhibitors
Cell Line, Tumor
Endothelial Cells
/ drug effects
Female
Immune Checkpoint Inhibitors
/ pharmacology
Immunotherapy
/ mortality
Lymphocyte Activation
/ drug effects
Lymphocytes, Tumor-Infiltrating
/ drug effects
Macrophages
/ drug effects
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Inbred NOD
Mice, SCID
Neoplasms
/ immunology
Th1 Cells
/ drug effects
Th2 Cells
/ drug effects
Tumor Microenvironment
/ drug effects
CTLs
H2O2
ICIs
VAP-1 inhibitor
immunosuppression
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
revised:
10
01
2021
received:
20
06
2020
accepted:
12
01
2021
pubmed:
17
1
2021
medline:
10
4
2021
entrez:
16
1
2021
Statut:
ppublish
Résumé
Modulation of the immunosuppressive tumor microenvironment (TME) is essential for enhancing the anti-tumor effects of immune checkpoint inhibitors (ICIs). Adhesion molecules and enzymes such as vascular adhesion protein-1 (VAP-1), which are expressed in some cancers and tumor vascular endothelial cells, may be involved in the generation of an immunosuppressive TME. In this study, the role of VAP-1 in TME was investigated in 2 murine colon cancer models and human cancer cells. Intraperitoneal administration of the VAP-1-specific inhibitor U-V296 inhibited murine tumor growth by enhancing IFN-γ-producing tumor antigen-specific CD8
Identifiants
pubmed: 33453147
doi: 10.1111/cas.14812
pmc: PMC8019209
doi:
Substances chimiques
Cell Adhesion Molecules
0
Immune Checkpoint Inhibitors
0
Amine Oxidase (Copper-Containing)
EC 1.4.3.21
semicarbazide-sensitive amine oxidase-vascular adhesion protein-1, mouse
EC 1.4.3.21
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1390-1401Subventions
Organisme : Japan Agency for Medical Research and Development
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 15K09783
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 19K16808
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 26221005
Informations de copyright
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Eur J Immunol. 1996 Jun;26(6):1308-13
pubmed: 8647210
Antioxid Redox Signal. 2019 Jan 20;30(3):314-332
pubmed: 29065711
Nat Rev Immunol. 2005 Oct;5(10):760-71
pubmed: 16200079
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W210-3
pubmed: 20478823
Sci Rep. 2017 Jan 13;7:40508
pubmed: 28084418
Melanoma Res. 2004 Apr;14(2):135-40
pubmed: 15057044
Basic Clin Pharmacol Toxicol. 2005 Jun;96(6):429-35
pubmed: 15910406
Eur J Immunol. 2003 Aug;33(8):2168-77
pubmed: 12884291
Biol Reprod. 2005 Oct;73(4):761-72
pubmed: 15958730
Cancer Res. 2009 Oct 1;69(19):7875-83
pubmed: 19789345
Metab Brain Dis. 2009 Mar;24(1):95-102
pubmed: 19104924
Int J Clin Oncol. 2020 May;25(5):810-817
pubmed: 31919690
FEBS Lett. 2017 Oct;591(19):3135-3157
pubmed: 28792588
J Immunol. 2014 Aug 1;193(3):1080-9
pubmed: 24965775
Immunity. 2005 Aug;23(2):153-63
pubmed: 16111634
Int J Cell Biol. 2012;2012:762825
pubmed: 22666258
Oxid Med Cell Longev. 2016;2016:1580967
pubmed: 27547291
Infect Immun. 1984 Jan;43(1):289-93
pubmed: 6360902
Am J Pathol. 2011 Apr;178(4):1913-21
pubmed: 21435467
Blood. 2009 Dec 17;114(26):5385-92
pubmed: 19861682
J Hepatol. 2001 Aug;35(2):297-306
pubmed: 11580156
Mol Immunol. 2008 Jan;45(1):58-64
pubmed: 17588662
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Cancer Res. 2001 Jun 15;61(12):4756-60
pubmed: 11406548
Cancer Immunol Immunother. 2005 Aug;54(8):721-8
pubmed: 16010587
J Immunol. 2001 Jun 1;166(11):6937-43
pubmed: 11359855
J Immunother. 2003 Jul-Aug;26(4):332-42
pubmed: 12843795
J Immunol Methods. 1997 Mar 28;202(2):133-41
pubmed: 9107302
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Nat Rev Cancer. 2018 Nov;18(11):681-695
pubmed: 30181570
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15792-7
pubmed: 21896719
Scand J Immunol. 2006 Feb;63(2):125-30
pubmed: 16476011
J Immunol. 2011 Apr 1;186(7):4147-55
pubmed: 21368224
Hepatology. 2010 Jun;51(6):2030-9
pubmed: 20512991
Cell Mol Immunol. 2018 Nov;15(11):953-962
pubmed: 29151581
J Immunol. 2010 Mar 15;184(6):3164-73
pubmed: 20154208
Cancer Sci. 2021 Apr;112(4):1390-1401
pubmed: 33453147
Nat Immunol. 2010 Oct;11(10):936-44
pubmed: 20729857
Cell Res. 2013 Jul;23(7):898-914
pubmed: 23752925
Mol Biol Cell. 2002 Jul;13(7):2502-17
pubmed: 12134086
Science. 2017 Nov 17;358(6365):941-946
pubmed: 29025995
J Immunol. 1998 Apr 15;160(8):3978-88
pubmed: 9558106
Crit Rev Clin Lab Sci. 2015;52(6):284-300
pubmed: 26287391
J Neural Transm (Vienna). 2007;114(6):845-9
pubmed: 17393060
Blood. 2014 Jan 30;123(5):625-31
pubmed: 24300855
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13119-24
pubmed: 8917554
Can J Physiol Pharmacol. 1987 Feb;65(2):141-5
pubmed: 3567730
J Clin Invest. 2015 Feb;125(2):501-20
pubmed: 25562318